ReviewJournal of gastroenterology2021
Clinical practice advice on lifestyle modification in the management of nonalcoholic fatty liver disease in Japan: an expert review.
Review in Journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Evidence summary of lifestyle interventions in adults with metabolic dysfunction-associated steatotic liver disease.Frontiers in nutrition · 2024Pooled it
- Comparative efficacy of Chinese patent medicines for non-alcoholic fatty liver disease: A network meta-analysis.Frontiers in pharmacology · 2022Pooled it
- The Metabolic Dysfunction-Associated Steatotic Liver Disease-CKD Axis: Intersecting Pathways and Opportunities for Early Intervention.Kidney international reports · 2026Review
- Metabolic Dysfunction-Associated Steatotic Liver Disease and Sarcopenia: Review of Literature.Journal of clinical medicine · 2026Review
- Development of a Neural Network to Detect Hepatic Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.Gastro hep advances · 2026Article
- Impact of aldehyde dehydrogenase 2 polymorphism on lipid profile alterations in alcohol-abstinent adolescents stratified by steatotic liver disease status.Environmental health and preventive medicine · 2026Article
- Review
- Long-term Favorable Efficacy of Regular and Repeated Hospitalizations with a Personalized Diet and Exercise Treatment for Steatotic Liver Disease.Internal medicine (Tokyo, Japan) · 2025Article
- Association between Sleep Duration and a New Onset of Nonalcoholic Fatty Liver Disease.Internal medicine (Tokyo, Japan) · 2024Article
- Self-management in patients with metabolic dysfunction-associated steatotic liver disease: influencing factors and impact on readmission.Journal of health, population, and nutrition · 2024Article
- Article
- Advancements in metabolic-associated steatotic liver disease research: Diagnostics, small molecule developments, and future directions.Hepatology research : the official journal of the Japan Society of Hepatology · 2024Review
- Barriers to lifestyle modification in patients with non-alcoholic fatty liver disease: a scoping review.Journal of rural medicine : JRM · 2024Article
- Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease.Nature reviews. Gastroenterology & hepatology · 2024Review
- Lifestyle factors affecting new-onset nonalcoholic fatty liver disease.Preventive medicine reports · 2024Article
- Article
- Lifestyle interventions in nonalcoholic fatty liver disease.Nature reviews. Gastroenterology & hepatology · 2023Review
- Body Composition Analysis in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease.Nutrients · 2023Article
- Blockade of C5aR1 alleviates liver inflammation and fibrosis in a mouse model of NASH by regulating TLR4 signaling and macrophage polarization.Journal of gastroenterology · 2023Article
- Risk of cardiovascular disease in lean patients with nonalcoholic fatty liver disease.BMC gastroenterology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 11 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver diseases worldwide, including in Japan. The Japanese Society of Gastroenterology (JSGE) and the Japanese Society of Hepatology (JSH) have established the Japanese NAFLD/NASH guidelines in 2014 and revised these guidelines in 2020. As described in these guidelines, weight reduction by diet and/or exercise therapy is important for the treatment of NAFLD patients. The I148M single nucleotide polymorphism (rs738409 C > G) of PNPLA3 (patatin-like phospholipase domain-containing 3 protein) is widely known to be associated with the occurrence and progression of NAFLD. In the Japanese, the ratio of PNPLA3 gene polymorphisms found is approximately 20%, which is higher than that found in Westerners. In addition, the ratio of lean NAFLD patients is also higher in Japan than in Western countries. Therefore, the method for lifestyle guidance for the NAFLD patients in Japan would be different from that for the people in Western countries. The problems in the treatment of NAFLD patients include alcohol consumption and sarcopenia. Therefore, guidelines that can help clinicians treat Japanese patients with NAFLD are needed. In this expert review, we summarize evidence-based interventions for lifestyle modification (diet, exercise, alcohol, and sarcopenia) for the treatment of patients with NAFLD, especially from Japan and Asian countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.